Statera Biopharma, Inc. (STAB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2021 | 21.16 Million USD | 1944.42% |
| 2020 | 1.03 Million USD | 62656.67% |
| 2019 | 1650.00 USD | -99.96% |
| 2018 | 4.53 Million USD | -52.91% |
| 2017 | 9.62 Million USD | -39.65% |
| 2016 | 15.95 Million USD | -23.59% |
| 2015 | 20.88 Million USD | -99.41% |
| 2014 | 3.54 Billion USD | -75.86% |
| 2013 | 14.69 Billion USD | -54.09% |
| 2012 | 32.01 Billion USD | 99535.92% |
| 2011 | 32.12 Million USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 Q3 | 12.74 Million USD | -5.86% |
| 2022 Q1 | 13.5 Million USD | -36.18% |
| 2022 Q2 | 13.54 Million USD | 0.24% |
| 2021 FY | 21.16 Million USD | 1944.42% |
| 2021 Q1 | 750.01 Thousand USD | -27.57% |
| 2021 Q2 | 32.1 Million USD | 4180.59% |
| 2021 Q3 | 98.03 Million USD | 205.36% |
| 2021 Q4 | 21.16 Million USD | -78.41% |
| 2020 Q3 | 3.23 Million USD | -20.79% |
| 2020 FY | 1.03 Million USD | 62656.67% |
| 2020 Q1 | 1.86 Million USD | -8.46% |
| 2020 Q2 | 4.07 Million USD | 118.77% |
| 2020 Q4 | 1.03 Million USD | -67.95% |
| 2019 FY | 1650.00 USD | -99.96% |
| 2019 Q1 | 3.77 Million USD | -16.64% |
| 2019 Q2 | 3.08 Million USD | -18.36% |
| 2019 Q3 | 2.22 Million USD | -27.77% |
| 2019 Q4 | 2.03 Million USD | -8.61% |
| 2018 Q4 | 4.53 Million USD | -20.42% |
| 2018 Q1 | 8.36 Million USD | -13.08% |
| 2018 Q2 | 7.05 Million USD | -15.69% |
| 2018 FY | 4.53 Million USD | -52.91% |
| 2018 Q3 | 5.69 Million USD | -19.25% |
| 2017 Q4 | 9.62 Million USD | -11.43% |
| 2017 Q1 | 13.88 Million USD | -13.0% |
| 2017 Q3 | 10.87 Million USD | -11.11% |
| 2017 FY | 9.62 Million USD | -39.65% |
| 2017 Q2 | 12.23 Million USD | -11.89% |
| 2016 Q4 | 15.95 Million USD | -6.31% |
| 2016 FY | 15.95 Million USD | -23.59% |
| 2016 Q2 | 17.96 Million USD | -9.3% |
| 2016 Q1 | 19.8 Million USD | -5.16% |
| 2016 Q3 | 17.02 Million USD | -5.19% |
| 2015 Q1 | 10.67 Million USD | -99.75% |
| 2015 Q4 | 20.88 Million USD | 335.68% |
| 2015 Q3 | -8.85 Million USD | 0.0% |
| 2015 FY | 20.88 Million USD | -99.41% |
| 2015 Q2 | - USD | -100.0% |
| 2014 Q1 | 17.66 Million USD | -99.88% |
| 2014 FY | 3.54 Billion USD | -75.86% |
| 2014 Q2 | 15.22 Million USD | -13.8% |
| 2014 Q4 | 4.32 Billion USD | 34580.69% |
| 2014 Q3 | 12.46 Million USD | -18.12% |
| 2013 FY | 14.69 Billion USD | -54.09% |
| 2013 Q1 | 25.18 Million USD | -99.92% |
| 2013 Q2 | 17.85 Million USD | -29.11% |
| 2013 Q4 | 14.69 Billion USD | 74541.05% |
| 2013 Q3 | 19.68 Million USD | 10.28% |
| 2012 Q4 | 32.01 Billion USD | 147640.81% |
| 2012 FY | 32.01 Billion USD | 99535.92% |
| 2012 Q1 | 26.51 Million USD | -17.46% |
| 2012 Q2 | 24.63 Million USD | -7.11% |
| 2012 Q3 | 21.66 Million USD | -12.04% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | 32.12 Million USD | 0.0% |
| 2011 Q4 | 32.12 Million USD | 14.23% |
| 2011 Q3 | 28.12 Million USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | -100.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | 6.55 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -6977.109% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -269.067% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -44.06% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 32.181% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -557.444% |
| Better Therapeutics, Inc. | 22.94 Million USD | 7.729% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 26.176% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -467.991% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3.046% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -0.221% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 67.149% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -799.418% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 70.182% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 19.017% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -27757.414% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -73.964% |
| Molecular Templates, Inc. | 35.38 Million USD | 40.17% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -384.254% |
| NexImmune, Inc. | 8.59 Million USD | -146.332% |
| Orgenesis Inc. | 14.55 Million USD | -45.476% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -79.374% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -16884.255% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -272.679% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -5296.782% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 95.523% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -109.497% |
| Trevena, Inc. | 40.6 Million USD | 47.864% |
| Vaxxinity, Inc. | 44.35 Million USD | 52.27% |
| Vaccinex, Inc. | 3.63 Million USD | -483.026% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -53283.309% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 62.658% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -3709.45% |